Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion
Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research
More News: Arrhythmia | Atrial Fibrillation | Bleeding | Cardiology | Coumadin | Heart | Ischemic Stroke | Pradaxa | Stroke | Study | Sweden Health | Vitamins | Warfarin